At CIMT 2016 Lytix presented LTX-315's ability to make tumors more T-cell inflamed
Øystein Rekdal (CSO) and Baldur Sveinbjørnsson (Senior researcher) represented Lytix Biopharma at the 14th CIMT Annual Meeting in Mainz, May 10-12, 2016.
This year Lytix Biopharma presented LTX-315's ability to enhance infiltration of CD8 positive T-cells in murine and human tumors, and T-cell clonality in B16 melanomas. These abilities make LTX-315 an ideal partner for beeing combined with other types of immunotherapy. The strong synergy between LTX-315 and anti-CTLA-4 in preclinical cancer model was also presented.
Øystein Rekdal and Baldur Sveinbjørnsson with the poster
The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. The CIMT Annual Meeting is Europe's largest specialty meeting on cancer immunotherapy research, translation, and development. The 2016 meeting is expected to attract 1,000 international attendees to Mainz, Germany.